Galmed PharmaceuticalsGLMD +2.71%27 FCF Yield % is -139.93 as of Jun. 24, 2026. GuruFocus rates GLMD with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Galmed Pharmaceuticals ranks worse than 93.3% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Galmed Pharmaceuticals FCF Yield % Related Terms
Galmed Pharmaceuticals FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Galmed Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galmed Pharmaceuticals FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Galmed Pharmaceuticals's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galmed Pharmaceuticals (GLMD) has a FCF Yield % of -139.93 as of Jun. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Galmed Pharmaceuticals and its competitors. According to the industry distribution chart, Galmed Pharmaceuticals ranks #1322 out of 1417 companies in the Biotechnology industry, placing it in the top 93.3%.
Is Galmed Pharmaceuticals' FCF Yield % too high?
Galmed Pharmaceuticals' current FCF Yield % is -139.93. Based on the distribution chart, Galmed Pharmaceuticals ranks #1322 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Galmed Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' FCF Yield % compare to RNAZ and ARTL?
According to the Biotechnology industry distribution chart, Galmed Pharmaceuticals ranks #1322 out of 1417 companies for FCF Yield %. This places Galmed Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Galmed Pharmaceuticals and its competitors. Galmed Pharmaceuticals's current FCF Yield % is -139.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (GLMD) has a current FCF Yield % of -139.93. The current FCF Yield % is -139.93. Galmed Pharmaceuticals' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Galmed Pharmaceuticals (GLMD), the current FCF Yield % is -139.93 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
27GF Score
Get the complete analysis for GLMD
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLMD has been successfully added to your 
